Bill > HB1619

This bill establishes two key provisions related to respiratory syncytial virus (RSV) disease in Arkansas: first, it mandates that the Arkansas Medicaid Program reimburse administration fees for RSV immunizations and monoclonal antibodies at 100% of the maximum administration fee under the Vaccines for Children Program, applicable to all beneficiary categories. The bill defines RSV as a respiratory infection affecting the nose, throat, and lungs, and ensures reimbursement for immunizations or monoclonal antibodies providing long-lasting protection for infants and toddlers. Second, the bill provides civil immunity to healthcare providers and entities involved in administering these RSV immunizations or monoclonal antibodies, with a critical caveat that this immunity does not extend to actions that are grossly negligent, reckless, willful, or not taken in good faith and with reasonable care. The legislation also requires the Department of Human Services to apply for any necessary federal waivers or Medicaid state plan amendments to implement these provisions, and clarifies that hospitals are not mandated to provide new or additional services beyond their current capabilities.

Health and Social Services

https://arkleg.state.ar.us/Bills/Detail?id=hb1619&ddBienniumSession=2025%2F2025R